PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
Abstract Background Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SC...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7125 |
| _version_ | 1797205673885302784 |
|---|---|
| author | Litang Huang Shen Chen Hui Liu Lu Meng Chengxing Liu Xiaoting Wu Yingying Wang Shilan Luo Hongbin Tu Chunlei Wang Ming Zhang Xiaomei Gong |
| author_facet | Litang Huang Shen Chen Hui Liu Lu Meng Chengxing Liu Xiaoting Wu Yingying Wang Shilan Luo Hongbin Tu Chunlei Wang Ming Zhang Xiaomei Gong |
| author_sort | Litang Huang |
| collection | DOAJ |
| description | Abstract Background Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC‐BMs). Methods We conducted a retrospective study by analyzing medical records of patients with SCLC‐BMs from January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), median progression‐free survival (mPFS), and intracranial progression‐free survival (iPFS) were analyzed. Results A total of 109 patients were enrolled, of which 60 received WBRT and 49 received WBRT‐ICI. Compared to the WBRT alone cohort, the WBRT‐ICI cohort showed longer mOS (20.4 months vs. 29.3 months, p = 0.021), mPFS (7.9 months vs. 15.1 months, p < 0.001), and iPFS (8.3 months vs. 16.5 months, p < 0.001). Furthermore, WBRT‐ICI cohort had a better response rate for both BMs. (p = 0.035) and extracranial diseases (p < 0.001) compared to those receiving WBRT alone. Notably, the use of WBRT before ICI was associated with longer mOS compared to the use of WBRT after ICI (23.3 months for the ICI‐WBRT group vs. 34.8 months for the WBRT‐ICI group, p = 0.020). Conclusion Our results indicated that WBRT combined with immunotherapy improved survival in SCLC‐BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC‐BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC‐BMs patients. |
| first_indexed | 2024-04-24T08:54:52Z |
| format | Article |
| id | doaj.art-eabe5290b4344061973fabc9b45307ef |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T08:54:52Z |
| publishDate | 2024-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-eabe5290b4344061973fabc9b45307ef2024-04-16T08:48:34ZengWileyCancer Medicine2045-76342024-04-01137n/an/a10.1002/cam4.7125PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidenceLitang Huang0Shen Chen1Hui Liu2Lu Meng3Chengxing Liu4Xiaoting Wu5Yingying Wang6Shilan Luo7Hongbin Tu8Chunlei Wang9Ming Zhang10Xiaomei Gong11Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai ChinaDepartment of Oncology, Shanghai Pulmonary Hospital Tongji University, School of Medicine Shanghai ChinaDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai ChinaDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai ChinaDepartment of Cardiology, Tongji Hospital Tongji University, School of Medicine Shanghai ChinaDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai ChinaDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai ChinaDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai ChinaDepartment of Integrated TCM and Western Medicine, Shanghai Pulmonary Hospital Tongji University, School of Medicine Shanghai ChinaDepartment of Endocrinology The Fourth Affiliated Hospital of Nantong University Jiangsu ChinaDepartment of Integrated Traditional Chinese and Western Medicine Shanghai Jiao Tong University School of Medicine, Shanghai Chest Hospital Shanghai ChinaDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University Shanghai ChinaAbstract Background Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC‐BMs). Methods We conducted a retrospective study by analyzing medical records of patients with SCLC‐BMs from January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), median progression‐free survival (mPFS), and intracranial progression‐free survival (iPFS) were analyzed. Results A total of 109 patients were enrolled, of which 60 received WBRT and 49 received WBRT‐ICI. Compared to the WBRT alone cohort, the WBRT‐ICI cohort showed longer mOS (20.4 months vs. 29.3 months, p = 0.021), mPFS (7.9 months vs. 15.1 months, p < 0.001), and iPFS (8.3 months vs. 16.5 months, p < 0.001). Furthermore, WBRT‐ICI cohort had a better response rate for both BMs. (p = 0.035) and extracranial diseases (p < 0.001) compared to those receiving WBRT alone. Notably, the use of WBRT before ICI was associated with longer mOS compared to the use of WBRT after ICI (23.3 months for the ICI‐WBRT group vs. 34.8 months for the WBRT‐ICI group, p = 0.020). Conclusion Our results indicated that WBRT combined with immunotherapy improved survival in SCLC‐BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC‐BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC‐BMs patients.https://doi.org/10.1002/cam4.7125extensive small cell lung cancerimmunotherapyintracranial metastasisradiotherapy |
| spellingShingle | Litang Huang Shen Chen Hui Liu Lu Meng Chengxing Liu Xiaoting Wu Yingying Wang Shilan Luo Hongbin Tu Chunlei Wang Ming Zhang Xiaomei Gong PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence Cancer Medicine extensive small cell lung cancer immunotherapy intracranial metastasis radiotherapy |
| title | PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence |
| title_full | PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence |
| title_fullStr | PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence |
| title_full_unstemmed | PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence |
| title_short | PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence |
| title_sort | pd l1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases real world evidence |
| topic | extensive small cell lung cancer immunotherapy intracranial metastasis radiotherapy |
| url | https://doi.org/10.1002/cam4.7125 |
| work_keys_str_mv | AT litanghuang pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT shenchen pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT huiliu pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT lumeng pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT chengxingliu pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT xiaotingwu pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT yingyingwang pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT shilanluo pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT hongbintu pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT chunleiwang pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT mingzhang pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence AT xiaomeigong pdl1inhibitorscombinedwithwholebrainradiotherapyinpatientswithsmallcelllungcancerbrainmetastasesrealworldevidence |